Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers

Sponsor
Coloplast A/S (Industry)
Overall Status
Completed
CT.gov ID
NCT04231149
Collaborator
(none)
10
1
3
1.5
6.8

Study Details

Study Description

Brief Summary

Performance and acceptance of new intermittent catheters tested in healthy volunteers

Condition or Disease Intervention/Treatment Phase
  • Device: Test product 2
  • Device: Test product 3
  • Device: Comparator
N/A

Detailed Description

This study is a single blinded, randomised, crossover study. The study period consists of an information visit, an inclusion visit, three test visits and a termination visit.

Two prototypes of intermittent catheters (Test product 2 and 3) compared to the standard catheter SpeediCath® Flex (Comparator).

In the investigation ten subjects will be included. The subjects will be catheterised once per visit. The subjects will be catheterised with the two test catheters and comparator in a randomised order. The order of the catheterisations will be randomised to prevent bias.

During the test visits the primary, secondary and explorative endpoints will be registered.

Subjects will be asked to participate in an interview in continuation of their last visit (Test Visit 3). The interviews will be performed by a Coloplast representative asking questions related to their experience with the catheter.

The subjects must sign a separate consent form for this purpose and can participate in the investigation without participating in the interview. In addition, subjects will be asked for consent to tape recording and filming during the interviews, but can participate in interviews without this.

In addition, a Coloplast representative will interview the Investigator and her representatives after LPO with questions related to their experience with the catheters.

The investigation is planned to be conducted in August 2018-Januar 2019. The visit window will be minimum five days between the visits (catheterisations), to ensure time for healing of any potential urethral trauma. However, the maximum time between visits should be adjusted to ensure the subject is terminated before LPO.

No biobank will be established for this investigation. All urine samples in the clinical investigation (for evaluating in- and exclusion criteria and for evaluating end points) will be destructed immediately after analysis.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Explorative Clinical Study Investigating the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers
Actual Study Start Date :
Nov 5, 2018
Actual Primary Completion Date :
Dec 20, 2018
Actual Study Completion Date :
Dec 20, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Test product 2

Test catheter 2

Device: Test product 3
Test catheter 3

Device: Comparator
SpeediCath Flex

Experimental: Test product 3

Test catheter 3

Device: Test product 2
Test catheter 2

Device: Comparator
SpeediCath Flex

Active Comparator: Comparator

SpeediCath Flex

Device: Test product 2
Test catheter 2

Device: Test product 3
Test catheter 3

Outcome Measures

Primary Outcome Measures

  1. Urine flow rate [4-5 weeks]

    Average flow rate of urine through the catheter

Secondary Outcome Measures

  1. Post void residual urine [4-5 weeks]

    Urine volume in the bladder post catheterisation

  2. Hematuria [4-5 weeks]

    Macroscopic and microscopic hematuria

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Has given written informed consent and signed letter of authority Is at least 18 years of age and has full legal capacity Is a male Willing to comply without using analgetica up to 24 hours prior to catheterisation visits

Exclusion Criteria:

Has a previous history of genitourinary disease including congenital abnormalities and surgical procedures performed in the urinary tract Has symptoms of urinary tract infections (frequent urination, stinging and pain at urination) Are participating in any other clinical investigation related to urinary tract system during this investigation (inclusion to termination) Known hypersensitivity toward any of the test products

Contacts and Locations

Locations

Site City State Country Postal Code
1 Coloplast A/S Humlebæk Denmark 3050

Sponsors and Collaborators

  • Coloplast A/S

Investigators

  • Principal Investigator: Birte Jakobsen, MD, Coloplast A/S

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Coloplast A/S
ClinicalTrials.gov Identifier:
NCT04231149
Other Study ID Numbers:
  • CP290
First Posted:
Jan 18, 2020
Last Update Posted:
Jan 23, 2020
Last Verified:
Jan 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jan 23, 2020